Phenomics, lipodystrophy, and the metabolic syndrome

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Disease Research
• Human Genetics

Background:

• Metabolic syndrome (MetS) is a cluster of conditions including central obesity, hypertension, dyslipidemia, and type 2 diabetes, significantly increasing cardiovascular disease risk.
• Insulin resistance is the central molecular defect in MetS, leading to the interchangeable use of 'MetS' and 'insulin resistance syndrome'.
• Advances in molecular genetics for rare monogenic metabolic disorders provide a framework for investigating genetic forms of insulin resistance.

Purpose of the Study:

• To evaluate rare monogenic forms of insulin resistance, such as partial lipodystrophy caused by LMNA or PPARG gene mutations.
• To explore the potential of detailed phenotypic evaluation ('phenomics') in carriers of monogenic insulin resistance.
• To identify early, presymptomatic biomarkers for cardiovascular disease associated with MetS and uncover novel therapeutic targets.

Main Methods:

• Phenotypic characterization of individuals with monogenic forms of insulin resistance.
• Utilizing a comprehensive diagnostic approach ('phenomics') to assess carriers.
• Genetic analysis of mutations in LMNA and PPARG genes associated with partial lipodystrophy.

Main Results:

• Identified rare monogenic forms of insulin resistance, exemplified by partial lipodystrophy linked to LMNA and PPARG mutations.
• Demonstrated the utility of phenomics in uncovering subtle or early signs of metabolic dysfunction.
• Highlighted the potential for identifying novel cardiovascular disease biomarkers in presymptomatic individuals.

Conclusions:

• Investigating rare monogenic insulin resistance syndromes can provide critical insights into the pathophysiology of common metabolic disorders like MetS.
• Phenomics offers a powerful strategy for early detection of disease risks and the discovery of new therapeutic targets.
• This approach may lead to improved interventions for MetS, type 2 diabetes, and atherosclerosis.